Skip to content
TrialScanner

NCT07157514

Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

Phase 2/Phase 3Not yet recruitingATNMLead

Registry record

Lead sponsor
Actinium Pharmaceuticals
Conditions
Acute Leukemia; Myeloid Leukemia; Acute Myelogenous Leukemia; Acute Myeloid Leukemia; Acute Myeloid Leukemia, in Relapse
Primary completion
Feb 2029Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT07157514 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.